Should I Buy REVB? REVB 2026 Analysis

Should You Buy Revelation Biosciences Inc (REVB) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

1.910

1 Day change

-8.85%

52 Week Range

55.200

Analysis Updated At

2026/01/26

Revelation Biosciences Inc (REVB) is not a strong buy for a beginner, long-term investor at this time. The stock is in a bearish technical trend, with no significant positive trading signals or strong financial performance to support a buy decision. While the FDA agreement for its Gemini drug is a positive catalyst, the company's financials remain weak, and the pre-market price is down significantly. It is better to wait for clearer signs of financial improvement or sustained positive momentum.

Technical Analysis

The technical indicators are bearish. The MACD is negative and expanding, RSI indicates the stock is oversold at 15.001, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The pre-market price is down 6.49%, and the stock is trading below key support levels (S1: 0.649).

Options Data

Positive Catalysts

The FDA agreement for a single Phase 2/3 adaptive study for its Gemini drug to treat acute kidney injury is a significant positive development. The stock also gained 25.22% in after-hours trading following this news.

Neutral/Negative Catalysts

The stock is down 6.49% in pre-market trading, indicating potential profit-taking or lack of sustained momentum. Financial performance remains weak, with negative net income and EPS, and no revenue growth.

Financial Performance

In 2025/Q3, the company showed no revenue growth (0% YoY), a net income of -$4,676,918 (up 108.65% YoY but still negative), and EPS dropped to -1.77 (-95.59% YoY). Gross margin remains at 0%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target data is available for REVB at this time.

Analyst Rating

Wall Street analysts forecast REVB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for REVB is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold

Sell

Current: 2.090

Low

Averages

High